SuperworthXeris Biopharma profit margin XERS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2022.
- Net margin, 12 months
- −5.1%
- Operating margin, 12 months
- 10.9%
- Net margin on a year earlier
- +7.9 pts
- Peer median
- 10.9%
Over the twelve months to Jun 30, 2026, Xeris Biopharma kept −5.1% of its revenue as net profit, with an operating margin of 10.9% and a gross margin of 86.6%.
The median for 10 large drugmakers of a similar size is 10.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 0.2% | 8.5% | 85.4% |
| FY2024 | −27.0% | −16.6% | 81.9% |
| FY2023 | −38.0% | −26.8% | 82.5% |
| FY2022 | −85.9% | −74.3% | 79.5% |
| FY2021 | n/a | n/a | 73.1% |
| FY2020 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −5.1% | +7.9 pts | 10.9% | |
| Q1 FY26 | 3.8% | +24.1 pts | 11.4% | |
| Q4 FY25 | 0.2% | +27.2 pts | 8.5% | |
| Q3 FY25 | −5.9% | +27.8 pts | 3.7% | |
| Q2 FY25 | −13.0% | +19.8 pts | −4.0% | |
| Q1 FY25 | −20.3% | +17.3 pts | −10.1% | |
| Q4 FY24 | −27.0% | +11.0 pts | −16.6% | |
| Q3 FY24 | −33.7% | +6.8 pts | −24.1% | |
| Q2 FY24 | −32.8% | +20.4 pts | −20.5% | |
| Q1 FY24 | −37.6% | +26.5 pts | −26.2% | |
| Q4 FY23 | −38.0% | +47.9 pts | −26.8% | |
| Q3 FY23 | −40.5% | n/a | −32.3% |
Against its peers
Companies in Drug Manufacturers - General nearest Xeris Biopharma's size, closest first, today.
| Company | Profit margin |
|---|---|
| XERSXeris Biopharma | −5.1% |
| ANIPANI Pharmaceuticals | 11.1% |
| HRMYHarmony Biosciences | 18.9% |
| PAHCPhibro Animal Health | 6.6% |
| PBHPrestige Consumer Healthcare | 15.6% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 2.0% |
| NRIXNurix Therapeutics | 42.0% |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OGNOrganon | 3.4% |
| Peer median | 10.9% |
Where Xeris Biopharma ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Xeris Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.